Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Iron Overload

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    82 result(s) found for: Iron Overload. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2008-003207-30 Sponsor Protocol Number: CICL670AES04 Start Date*: 2008-10-01
    Sponsor Name:NOVARTIS FARMACEUTICA S.A
    Full Title: Ensayo abierto, no aleatorizado, multicéntrico, que evalúa la eficacia y seguridad de deferasirox (Exjade®) en pacientes con sobrecarga férrica después de un trasplante alogénico de progenitores he...
    Medical condition: Pacientes que presenten evidencia de sobrecarga férrica (ferritina sérica ≥1000 ng/ml) entre 6 y 18 meses después de un TPH alogénico (independientemente de la enfermedad subyacente y del ré...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065973 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-010088-17 Sponsor Protocol Number: MID/09 Start Date*: 2009-02-16
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI GALLIERA
    Full Title: Whole liver iron overload measured by the biosusceptometer Magnetic Iron Detector (MID) in thalassemia and MDS patients treated with deferasirox
    Medical condition: Patients with diagnosis of thalassemia major with iron overload or regularly transfused MDS patients (Low/Intermediate-1 IPSS risk and 1 year life expectancy)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010329 Congenital anaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000650-64 Sponsor Protocol Number: CICL670E2419 Start Date*: 2012-11-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, multi-center, efficacy and safety study of deferasirox in iron overloaded patients with non-transfusion dependent thalassemia (THETIS)
    Medical condition: iron overload in patients with non-transfusion dependent thalassemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10022979 Iron excess HLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2018-004016-22 Sponsor Protocol Number: LA61-0218 Start Date*: 2018-12-27
    Sponsor Name:ApoPharma Inc.
    Full Title: Safety and acceptability of deferiprone delayed release tablets in patients with systemic iron overload
    Medical condition: Systemic iron overload
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10065973 Iron overload PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001561-88 Sponsor Protocol Number: CICL670ATRO4 Start Date*: 2016-04-14
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A Phase II, Multi-center, Single-arm, Prospective Study to Evaluate the Safety and Efficacy of Deferasirox in Beta-thalassemia Major Patients After Hematopoietic Stem Cell Transplantation
    Medical condition: -Iron overload
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-001077-13 Sponsor Protocol Number: CICL670A2417 Start Date*: 2011-08-11
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: Estudio clínico multicéntrico, aleatorizado, comparativo, de distintos regímenes de administración de deferasirox en la tolerabilidad gastrointestinal (GI), en pacientes con síndrome mielodisplásic...
    Medical condition: Sobrecarga de hierro de riesgo bajo o intermedio (int-1) en pacientes con síndrome mielodisplásico (SMD) con ferritina > 1000 mcg/L en la selección o antecedentes de transfusión de por lo menos 20 ...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10022979 Iron excess HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-004008-10 Sponsor Protocol Number: CICL670AHU02 Start Date*: 2008-01-08
    Sponsor Name:Novartis Hungária Kft.
    Full Title: Evaluating the efficacy of Exjade® (deferasirox) in transfusion dependent chronic anaemias ( Myelodysplasia Syndrome, Beta-thalassaemia major patients) with chronic iron overload
    Medical condition: In- or outpatients with myelodysplasia or beta thalassaemia major, who have chronic iron overload, as a consequence of frequent blood transfusion
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2011-005675-16 Sponsor Protocol Number: FBS0701-CTP-16 Start Date*: 2012-05-15
    Sponsor Name:FERROKIN BIOSCIENCES INC.
    Full Title: A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two FBS0701 Doses in the Treatment of Chronic Iron Overlo...
    Medical condition: Patients with transfusional iron overload, with the following primary diagnosis:hereditary anemia (such as sickle cell disease),β-thalassemia and Diamond Blackfan anemia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017409-13 Sponsor Protocol Number: MD2009.04 Start Date*: 2010-06-30
    Sponsor Name:Sanquin Plasma Products
    Full Title: Dose escalating study to evaluate pharmacokinetics, efficacy and safety of apotransferrin in atransferrinemia patients. Estudio de escalada de dosis para evaluar la farmacocinÊtica, la eficacia y l...
    Medical condition: Atransferrinemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10044357 Transferrin increased LLT
    12.1 10005620 Blood iron increased LLT
    12.1 10002272 Anemia LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003970-89 Sponsor Protocol Number: CICL670ADE02 Start Date*: 2007-12-21
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 (20 mg/kg/day) in patients three to six months after allogeneic hematopoietic cell transplan...
    Medical condition: allogeneic hematopoietic cell transplantation with iron overload
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001756 Allogenic bone marrow transplantation therapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001718-32 Sponsor Protocol Number: FBS0701CTP-07 Start Date*: 2011-09-07
    Sponsor Name:FERROKIN BIOSCIENCES INC.
    Full Title: A Phase 2, Open Label, Multi-Center, Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of FBS0701 in a Pediatric Population with Transfusional Iron Over...
    Medical condition: Patients with documented transfusional iron overload ages 6 to less than 18 years old will be studied. Patients with transfusion-dependent anemias will be eligible regardless of the cause of thei...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10065974 Chronic iron overload LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000743-33 Sponsor Protocol Number: SPD602-204 Start Date*: 2014-01-16
    Sponsor Name:Shire Development LLC and International Affiliates
    Full Title: A 48-week, Open-label, 2-arm, Parallel-group, Randomized Exploratory Study to Assess Liver Iron Concentration Measured by FerriScan® (R2) Magnetic Resonance Imaging in β-thalassemia Subjects Admin...
    Medical condition: Patients 18 years of age and older with transfusional iron overload due to β-thalassemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10065974 Chronic iron overload LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-006322-25 Sponsor Protocol Number: SPD602-301 Start Date*: 2012-10-08
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602).
    Medical condition: Patients with transfusional iron overload due to hereditary anemias such as sickle cell disease, beta-thalassemia and Diamond-Blackfan anemia; aquired anemias such as Myelodysplastic Syndrome and o...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10065974 Chronic iron overload LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002583-14 Sponsor Protocol Number: CICL670A2201 Start Date*: 2016-11-25
    Sponsor Name:Novartis Pharmaceuticals Corp
    Full Title: A Randomized, Open-label, Multi-center, Phase II Study to Evaluate the Safety and Efficacy of Deferasirox (ICL670) 20 mg/kg/Day Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients...
    Medical condition: Sickle Cell Disease/ Iron Overload
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-003777-34 Sponsor Protocol Number: NL63198.041.17 Start Date*: 2018-02-09
    Sponsor Name:UMC Utrecht
    Full Title: Proton pump inhibition for secondary hemochromatosis in hereditary anemia, a phase III placebo controlled randomized cross-over clinical trial.
    Medical condition: Iron overload (secondary hemochromatosis) in non-transfusion dependent forms of hereditary anemias. Iron overload and hereditary anemia are a growing, underestimated emerging health care problem.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002272 Anemia LLT
    20.0 100000004861 10057875 Secondary haemochromatosis LLT
    20.0 100000004861 10022979 Iron excess HLT
    20.0 100000004850 10055610 Hemoglobinopathy LLT
    20.0 100000004850 10074356 Non-transfusion dependent thalassemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003542-17 Sponsor Protocol Number: FISM_IRON-MDS Start Date*: 2019-05-06
    Sponsor Name:FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE ETS
    Full Title: Early and low dose Deferasirox (3.5 mg/kg FCT) to suppress NTBI and LPI as early intervention to prevent tissue iron overload in lower risk MDS
    Medical condition: Adult patients with low risk MDS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028532 Myelodysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003531-35 Sponsor Protocol Number: CICL670ARU01 Start Date*: 2016-03-07
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: 1 Year, Open-label Multicenter Evaluation of Efficacy, Safety of Deferasirox in Patients MDS, Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10054658 Thalassemia LLT
    19.0 100000004864 10028534 Myelodysplastic syndrome NOS LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-018091-34 Sponsor Protocol Number: CICL670AGR02 Start Date*: 2010-07-14
    Sponsor Name:Novartis (Hellas) S.A.C.I
    Full Title: A multicenter open label phase II study to evaluate the safety and efficacy of deferasirox in combination with deferioxamine followed by transitioning to deferasirox monotherapy in β-thalassemia pa...
    Medical condition: Chronic iron overload in patients cardiac iron overload and β thalassemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10043389 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019645-25 Sponsor Protocol Number: SPD602-201 Start Date*: 2010-07-19
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, and Pharmacodynamics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation T...
    Medical condition: Patients with transfusional iron overload due to hereditary anemias such as sickle cell disease, β-thalassemia and Diamond-Blackfan anemia; acquired anemias such as Myelodysplastic Syndrome and oth...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10065974 Chronic iron overload LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000658-67 Sponsor Protocol Number: DEEP-1 Start Date*: 2012-07-31
    Sponsor Name:Consorzio per Valutazioni Biologiche e Farmacologiche
    Full Title: Multi-centre, oral single dose experimental and modelling study to evaluate the pharmacokinetics of deferiprone in patients aged from 1 month to less than 6 years of age affected by transfusion-dep...
    Medical condition: chronic iron overload
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10065974 Chronic iron overload LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 05 00:17:25 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA